Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Anthony B. El-Khoueiry, Jörg Trojan, Tim Meyer, Thomas Yau, Ignacio Melero, Masatoshi Kudo, Chih‐Hung Hsu, T.-Y. Kim, Su Pin Choo, Yubin Kang, Winnie Yeo, Akhil Chopra, Samira Soleymani, J. Yao, Jaclyn Neely, Marina Tschaika, Theodore H. Welling, Bruno Sangro
Topics & Concepts
SorafenibMedicineHepatocellular carcinomaTolerabilityNivolumabInternal medicineAdverse effectOncologyResponse Evaluation Criteria in Solid TumorsGastroenterologyPhases of clinical researchToxicityCancerImmunotherapyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCancer Mechanisms and Therapy